PHP43 The High Cost of Treating Cancer: Do Manufacturer Pricing Policies Take Affordability Into Account?  by Akpinar, P. & Saraf, S.
main categories of risks were identified which could affect on accessibility and
quality named financial, supply, production, storage and logistic risks andin each
category there were several uncertainties. Inflation rate, exchange rate, incorrect
pricing, selection of suppliers, delay in shipment, policy issues, malfunction of
machineries, untrained personnel and inappropriate condition of storage and dis-
tribution are some of risks in different categories. All of these risks had direct or
indirect effect on quality or accessibility of medicines. CONCLUSIONS: Our study
offers risk assessment methodology as a scientific way for identification of uncer-
tainties which affect on quality and accessibility of medicines as two main objec-
tives of national drug policy and also it demonstrated some proper strategies to
mitigate them.
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OBJECTIVES: We examine how much of the cross-country drug price differences
can be explained by macroeconomic conditions (real GDP per capita, openness,
population, and corruption). METHODS: We use the Pricentric® dataset of drug
prices and analyze prices of 13 drug packs across 32 countries at various pack levels
in 2009. The sample is selected by requiring each pack having observations for
more than 20 countries and each country having observations for more than 20
packs. We gather data on real GDP per capita, openness, and population from the
PennWorld Table, and the Corruption Perceptions Index by Transparency Interna-
tional. The analysis has two parts. First, for each drug pack, we regress the log
prices (ex-factory, public, etc) on the four macroeconomic variables. Second, to
achieve better identification, we pool together all data and regress log prices on the
macroeconomic variables and drug fixed effects. RESULTS: For 6 of the 13 packs we
find that the four macroeconomic variables can explain the cross-country price
variations well (with R-squared over 8%). For the other 7 drugs the fit is worse, but
the signs of the coefficients among the 13 packs are in general consistent. The
pooled regression shows the same conclusion that the macroeconomic variables
have strong explanatory power. For thewhole sample, a 1% increase in real GDPper
capita correlates with a 0.15% increase in drug price. Openness has little impact,
while population has a small but significant positive association. A 1% increase in
the corruption index correlates with a 0.3% increase for all prices. CONCLUSIONS:
Controlling for drug fixed effects, macroeconomic variables show statistically sig-
nificant and economically large effects on drug pack prices. In particular, real GDP
per capita and corruption perceptions have large positive impacts suggesting drugs
cost more in either more developed countries or in more corrupted countries.
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OBJECTIVES: In 2008, GLOBOCAN estimated 2.8 million new cases of cancer in
China, making up 22% of all global cases. Although the Chinese government has
initiated a number of reforms to improve patient care, oncology drug access re-
mains a significant issue with medicines not being on national lists of essential or
reimbursed drugs. In China, manufacturers often set the price of oncology drugs
free of government mandates as these are not reimbursed. In contrast, in markets
where governments fund cancer treatment (South Korea, Japan, Taiwan), all med-
icines are assessed and undergo price setting/negotiation. Given these dynamics
and discussion by pharma companies to price medicines more in line with afford-
ability, this research explores the price differences for oncology agents across dif-
ferent types of markets taking into account the purchasing power parity and level
of patient access. METHODS: Review current prices of selected oncology agents
and the level of patient access across the Asian markets. Compare uptake of drugs
and identify drivers for access and uptake. Analyze prices relative to purchasing
power parity and compare to US& EU. RESULTS:The price differential across Asian
markets is correlated with lack of reimbursement, i.e., higher prices in countries
where there is no likelihood of reimbursement. In contrast, in countries where
these drugs are reimbursed, prices are tightly controlled and subject to regular
price cuts. Affordability remains the major challenge for access to cancer drugs.
CONCLUSIONS: Currently, innovative cancer drugs are outside the reach of most
Chinese as drug prices are some of the highest in the world. As the government
aims to reimbursemore oncology therapies, it will need to agree withmanufactur-
ers on price levels. Asianmarkets with ability to secure patient access tomedicines
at regulated prices can be useful models for China as the government looks to
improve the system.
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OBJECTIVES:Ourmajor objective of the studywas to assess the budgetary outcome
of implementing the first Hospital Essential Medicines List (HEML) 2011 with a
revised purchase policy in a rural resource limited, district charity hospital in India.
HEML was also compared with national and World Health Organization (WHO)
EMLs. METHODS: Expenditure on medicines purchase for the year of 2010 was
compared for the year 2011 (after the first HEML and revised purchase policy).
Evaluations were done to compare the number of medicines, dosage forms and
fixed drug combinations of tablets and injections. Microsoft Excel 2007 was used to
process the results. RESULTS: There was approximately 40 % reduction in the
money spent on medicines in 2011 when compared to 2010, which was approxi-
mately nine crores of Indian Rupees (approximately 1.7 Million US Dollars). The
number of medicines in 2010 was 1627, which was reduced to 424 in HEML 2011.
WHOEML 2011 has 350 and National Essential Drugs List (NEDL) 2011 of India has
348 medicines. While preparing the HEML, 31 tablets and 14 injections of two-drug
fixed combinationswere removed. The great reductionswere; 51 ointments to 9, 69
drops to 5, 11 paste to 0, 21 solutions to 3 and 14 creams to 1. The dosage forms
removed include elixir, insulin pen, gums, paste, paint, gargle, mouthwash.
CONCLUSIONS: New purchasing policy and implementation of HEML were the
crucial factors in the cost minimization, in our charitable hospital. The WHOEML
2011, NEML 2011 and the HEML 2011 were comparable with few exceptions. Health
care policy makers should note that, use of WHOEML and NEML with local experi-
ence makes implementation of HEML more practical in the countries with limited
professional resources.
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Compliance is an important factor for successful clinical management of schizo-
phrenia. Risperidone long-acting injection (RLAI) can improve compliance com-
pared to oral atypical anti-psychotics and several studies found the use of RLAIwas
associated with reduced hospitalization. RLAI was introduced to Japanese practice
from June 2009 and is currently only available atypical anti-psychotic depot
medication. OBJECTIVES: To assess the impact of RLAI use on hospitalization as a
proxy of relapse in daily practice among Japanese patients with schizophrenia.
METHODS: Mirror image comparison of psychiatric related hospitalization was
made for 6 months before (pre-RLAI) and 6 months after (post-RLAI) the initiation
of RLAI. The data source was commercially available health insurance claims da-
tabase (Japan Medical Data Center, Tokyo; January, 2009 to June, 2011). The inclu-
sion criteria were patients (20-59 years of age) who were diagnosed with schizo-
phrenia (ICD F20 to F29) and who had continuous enrollment of the Group health
insurance for 6 months before and 6 months after the initiation of RLAI. Patients
with long-term hospitalization (6 months) were excluded. Additionally, study
patients were restricted to have at least 3 month continuous treatment with RLAI.
In the analysis the initiation of RLAI during hospitalization contributed to pre-RLAI
hospitalization because previous treatment was considered as failure. RESULTS: A
total of 25 patients from 58 patients who were initiated on RLAI met the inclusion
criteria. Twenty patients started at outpatient visits and 21 patients continued the
RLAI treatment after 6 months. Mean dose was 33.5mg. The proportion of patients
requiring psychiatric hospitalization was changed from 28% to 8% between pre-
and post-initiating RLAI (P001). The total number of psychiatric hospitalization
was reduced by 82% (11 vs. 2, P0.02). CONCLUSIONS: Switching from oral anti-
psychotics to RLAImay impact on the reduction in hospitalization among Japanese
schizophrenic patients. Further investigation is necessary.
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OBJECTIVES: To estimate the annual prevalence, the related medical costs, and
health care resource utilization of patients diagnosed as herpes zoster (HZ) and
post-herpetic neuralgia (PHN), respectively, with different immune status in South
Korea.METHODS: This study is a retrospective analysis using the Korean National
Patients Sample 2009 database of the Health Insurance Review and Assessment
Service (HIRAK-NPS). Results of the sample databasewere extrapolated to the total
Korean population aged  40 years. HZ and PHN patients were identified from
diagnostic codes, and categorized into three subgroups based on the severity of
immune status; non-compromised, mild to moderate and severe status. Medical
costs included all HZ- or PHN-related costs incurred at medical facilities and med-
ication costs. RESULTS: The prevalence of HZ (or PHN) was 15.53 (or 2.13) per 1000
persons among those aged 40 years in South Korea. The annualmedical costs per
patient for HZ (or PHN)managementwere US$191 (or $177). The average number of
outpatient visits, emergency department visits and hospital admissions of HZ (or
PHN) patients were 3.75, 0.01, and 0.05 (4.44, 0.01, and 0.03) per annum, respec-
tively. With regard to the severity of immunodeficiency, patients with severe con-
ditions were related to higher prevalence rate, medical costs and health care
utilization. CONCLUSIONS: HZ and PHN cause considerable disease burden in
South Korea, especially among immunocompromised population. Considering
rapidly aging population and increasing prevalence of immunosuppressive condi-
tions, the disease burden is likely to increase. The findings of the present study can
serve as important baseline data for policy decision making to reduce the burden,
such as the development of a HZ vaccination recommendation.
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